MEDNAX MD 深 沪
等待开盘 09-24 09:30:00 美东时间
16.48
-0.080
-0.48%
华盛通- 最 高16.73
- 今 开16.53
- 成交量 57.09万股
- 最 低 16.47
- 昨 收 16.56
- 总市值 14.16亿
- 52周最高 17.67
- 市盈率 静 --
- 换手率 0.66%
- 52周最低 11.59
- 委 比 70.11%
- 总股本 8590.57万
- 历史最高 112.89
- 量 比 0.64
- 振 幅 1.57%
- 历史最低 6.62
- 每 手 1
- 风险率 1.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aytu outlines EXXUA launch targeting $22B MDD market while streamlining ADHD portfolio
Earnings Call Insights: Aytu BioPharma (AYTU) Q4 2025 Management View CEO Joshua Disbrow highlighted "the strong financial performance during the recent fiscal year and perhaps more importantly, the u...
今天 09:44
KMD Brands Reports Financial Loss Despite Revenue Growth
The latest announcement is out from KMD Brands Limited ( ($AU:KMD) ). KMD Brand...
今天 06:02
Demystifying ATAI Life Sciences: Insights From 5 Analyst Reviews
In the latest quarter, 5 analysts provided ratings for ATAI Life Sciences (NASD...
今天 06:00
Meridian Health Plan of Illinois Rewards Providers with $15M for Improved Health Outcomes
Meridian and its providers are increasing access to high-quality care for over 340,000 Medicaid members statewide through value-based partnerships, resulting in a 21% reduction in emergency ...
09-23 21:46
Illumina advances personalized cancer care with new pharma development partnerships
Illumina and pharma partners will develop companion diagnostics for historically important KRAS biomarker SAN DIEGO, Sept. 23, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) will partner ...
09-23 21:15
复宏汉霖HLX22治疗胃癌的头对头III期临床完成阿根廷首例患者给药
内容来源：复宏汉霖 2025年9月23日，复宏汉霖宣布，公司新表位HER2单抗HLX22头对头对比一线标准疗法（曲妥珠单抗+化疗±帕博利珠单抗）的国际多中心I...
09-23 20:21
不再跟随，而是定义！中国先进医疗器械的「DeepSeek时刻」
长久以来，在全球先进医疗器械的创新版图中，中国企业的角色多以“跟随者”出现——引进消化、模仿迭代、成本优化。尤其是在心血管、神经介入、肿瘤治疗等尖端领域，核心技...
09-23 16:06
SK keyfoundry推出新型多层厚金属间电介质工艺
SK keyfoundry宣布推出具备业界领先高击穿电压特性的多层厚金属间电介质 (Thick IMD)电容工艺。该工艺支持堆叠最多三层IMD，每层最大厚度达...
09-23 13:02
国泰海通：予诺诚健华“增持”评级 目标价26.7港元
国泰海通发布研报称，予诺诚健华（09969）“增持”评级，预计2025-27年公司营收分别为14.43/18.59/26.91亿元，分别同比增长43/29/4...
09-23 11:57
Immutep Initiates Phase II Trial Of Efti As Monotherapy And With Chemotherapy For Early-Stage HR+/HER2- Breast Cancer
GW Cancer Center to initiate Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in HR+/HER2-neg breast cancer patients Second investigator-initiated trial
09-22 20:17
